The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC.
 
Hans Prenen
Honoraria - Amgen; Bayer; Roche; Sanofi; Vifor Pharma
Travel, Accommodations, Expenses - Amgen; Bayer; Roche
 
Jeroen Dekervel
No Relationships to Disclose
 
Alain Hendlisz
No Relationships to Disclose
 
Sébastien Anguille
No Relationships to Disclose
 
Ahmad Awada
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Genomic Health; Ipsen; LEO Pharma; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche
Speakers' Bureau - Lilly
Research Funding - Bristol-Myers Squibb; MSD
 
Emilie Cerf
Employment - Celyad Oncology
 
Caroline Lonez
Employment - Celyad
Stock and Other Ownership Interests - Celyad
 
Eytan Breman
Employment - Celyad Oncology
 
Marie-Sophie Dheur
Employment - Celyad Oncology
 
Erik Alcantar-Orozco
Employment - Celyad Oncology
 
David Edward Gilham
Employment - Celyad Oncology
Stock and Other Ownership Interests - Celyad Oncology
 
Anne Flament
Employment - Celyad Oncology
 
Frederic Lehmann
Employment - Celyad Oncology
Leadership - Celyad Oncology
Stock and Other Ownership Interests - Celyad Oncology
Honoraria - Celyad Oncology
Patents, Royalties, Other Intellectual Property - GlaxoSmithKline
Travel, Accommodations, Expenses - Celyad Oncology
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)